184 related articles for article (PubMed ID: 19568750)
1. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
Sun N; Sun X; Chen B; Cheng H; Feng J; Cheng L; Lu Z
Cancer Chemother Pharmacol; 2010 Feb; 65(3):437-46. PubMed ID: 19568750
[TBL] [Abstract][Full Text] [Related]
2. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
3. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
Han ZG; Tao J; Yu TT; Shan L
Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
[TBL] [Abstract][Full Text] [Related]
4. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
Zhao R; Chen G
Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
[TBL] [Abstract][Full Text] [Related]
5. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.
Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J
Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
Bu L; Zhang LB; Mao X; Wang P
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
[TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
[TBL] [Abstract][Full Text] [Related]
10. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Zhou F; Yu Z; Jiang T; Lv H; Yao R; Liang J
Swiss Med Wkly; 2011; 141():w13275. PubMed ID: 22009704
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
13. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Wang ZH; Miao XP; Tan W; Zhang XR; Xu BH; Lin DX
Ai Zheng; 2004 Aug; 23(8):865-8. PubMed ID: 15301704
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A
Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Wang H; Gao X; Zhang X; Gong W; Peng Z; Wang B; Wang L; Chang S; Ma P; Wang S
Med Sci Monit; 2018 Oct; 24():7482-7492. PubMed ID: 30341887
[TBL] [Abstract][Full Text] [Related]
16. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
17. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
18. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
19. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
